CAVA Group Inc vs ClearPoint Neuro Inc — how do they compare? CAVA Group Inc trades at $67.89 (market cap $7.17B), while ClearPoint Neuro Inc trades at $14.92 (market cap $444.14M). The key difference: CAVA Group Inc is far larger — about 16.1× ClearPoint Neuro Inc's market cap, and CAVA Group Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CAVA | CLPT | |
|---|---|---|
Market Cap | $7.17B | $444.14M |
Sector | Consumer Cyclical | Health |
52-Week High | $97.39 | $29.60 |
52-Week Low | $43.59 | $8.66 |
Enterprise Value | $7.32B | $478.72M |
Signals from Pluang's Aura AI — not financial advice
CAVA trades at $62.42, up 0.31% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $1.18B in 2025 and has beaten earnings estimates in two of the last three quarters. Recent news highlights anticipation for the Q2 2026 earnings report, with analysts citing strong traffic and expansion as positive catalysts.
Wall Street maintains a bullish outlook with a consensus price target of $91.00, though high valuation multiples and recent net cash outflows pose risks. The stock's investment case hinges on continued execution of its growth strategy amid competitive industry pressures.
ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.
The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.
Trailing returns across standard periods
Latest headlines on both assets
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →